Can Paxlovid Improve Long COVID Symptoms?
(MedPage Today) -- In this interview, Jeremy Faust, MD, editor-in-chief of MedPage Today, talks with Harlan Krumholz, MD, SM, of Yale School of Medicine in New Haven, Connecticut, about his ongoing study testing nirmatrelvir-ritonavir (Paxlovid... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - November 30, 2023 Category: Infectious Diseases Source Type: news
COVID Rebound May Occur in 20% of Paxlovid Users
(MedPage Today) -- A new study in Annals of Internal Medicine suggests that one in five COVID patients who take nirmatrelvir/ritonavir (Paxlovid) may experience viral rebound, a far higher proportion than seen in prior analyses.
In this video... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - November 15, 2023 Category: Infectious Diseases Source Type: news
Virologic Rebound Occurs in ~20 Percent Receiving Nirmatrelvir-Ritonavir
TUESDAY, Nov. 14, 2023 -- For patients receiving nirmatrelvir-ritonavir (N-R) for acute COVID-19, virologic rebound (VR) occurs in about one in five, according to a study published online Nov. 14 in the Annals of Internal Medicine.
Gregory E.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 14, 2023 Category: Pharmaceuticals Source Type: news
Rebound Infections Occur in 20% of Paxlovid Users, According to New Research
COVID-19 has become less of an urgent threat than it was in 2019 largely because of vaccines and growing immunity from natural infections, but antiviral treatments have also changed the course of the disease. The most popular of these is nirmatrelvir-ritonavir, sold under the brand name Paxlovid, which the U.S. Centers for Disease Control and Prevention (CDC) recommends for older people and anyone over age 12 who is at higher risk of COVID-19 complications. But people taking the drug have reported incomplete recovery, or testing positive again after testing negative once they finished the five-day course of the oral medica...
Source: TIME: Health - November 14, 2023 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
Paxlovid Not Helpful for Reducing Most Post-COVID-19 Conditions
TUESDAY, Oct. 31, 2023 -- Outpatient treatment of COVID-19 with nirmatrelvir-ritonavir (Paxlovid) reduces the risk for combined thromboembolic events, but does not affect the risk for other post-COVID-19 conditions (PCCs), according to a study... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 31, 2023 Category: Pharmaceuticals Source Type: news
Paxlovid Priced at $1,390! Snoozing the Alarm and Health; Medical Aid Heads to Gaza
(MedPage Today) -- Note that some links may require registration or subscription.
Pfizer is jacking up the list price of its COVID antiviral nirmatrelvir-ritonavir (Paxlovid) to $1,390 when it moves to commercial sales. (Reuters)
Speaking of... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 19, 2023 Category: Infectious Diseases Source Type: news
Mixed Signals for Paxlovid and Long COVID Risk in CDC Study
(MedPage Today) -- Use of nirmatrelvir-ritonavir (Paxlovid) during the acute phase of COVID-19 appeared to significantly reduce the risk of post-COVID conditions (PCCs) in older adults at high risk for severe disease, but may have increased the... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - October 16, 2023 Category: Infectious Diseases Source Type: news
Improved Pharma at AAPS 2023 PHARMSCI 360 with booth #3323, two posters, and an invited talk as a Speaker Spotlight
Poster M1230-08-49 on a late appearing form of Ritonavir, poster W0930-08-54 on PDF/ESPR modeling to understand hydrogen bonding in amorphous Indomethacin, and a Speaker Spotlight in the Formulation & Delivery session with Dr. Stephen Byrn. WEST LAFAYETTE, Ind., Oct. 10, 2023... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 10, 2023 Category: Pharmaceuticals Tags: TDS Source Type: news
Paxlovid Tied to Benefits in High-Risk Patients With COVID Paxlovid Tied to Benefits in High-Risk Patients With COVID
The use of nirmatrelvir –ritonavir (Paxlovid) is associated with a lower risk for death or hospitalization in extremely vulnerable patients with COVID-19. Low-risk patients do not appear to benefit.Medscape Medical News (Source: Medscape Infectious Diseases Headlines)
Source: Medscape Infectious Diseases Headlines - October 10, 2023 Category: Infectious Diseases Tags: Infectious Diseases News Source Type: news
Nirmatrelvir/Ritonavir Cuts COVID-19 Complications in Highest-Risk Patients
WEDNESDAY, Oct. 4, 2023 -- For individuals with the highest risk for complications from COVID-19 infection, nirmatrelvir and ritonavir is associated with a reduced risk for COVID-19 hospitalization or death, according to a study published online... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - October 4, 2023 Category: Pharmaceuticals Source Type: news
Are Paxlovid and Lagevrio Equals?
(MedPage Today) -- Both nirmatrelvir-ritonavir (Paxlovid) and molnupiravir (Lagevrio) were associated with a reduction in death during the COVID-19 Omicron era, a large retrospective study of electronic health records from the Cleveland Clinic... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - September 21, 2023 Category: Infectious Diseases Source Type: news
Role for Paxlovid in Younger COVID Patients With Serious Comorbidities
(MedPage Today) -- The benefit of nirmatrelvir-ritonavir (Paxlovid) for high-risk COVID-19 outpatients appears to extend to younger vaccinated adults with serious comorbidities, retrospective data suggested.
In a propensity-score matched analysis... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - July 7, 2023 Category: Infectious Diseases Source Type: news
Stanford Study of Paxlovid for Long COVID Stopped Early
(MedPage Today) -- Enrollment into a small trial of nirmatrelvir/ritonavir (Paxlovid) for long COVID -- one that previously garnered attention for investigators not wearing masks -- has been stopped early after an interim analysis, Stanford... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - June 30, 2023 Category: American Health Source Type: news
Dolutegravir Switch Maintains Second-Line HIV Suppression
(MedPage Today) -- Switching people living with HIV from a ritonavir-boosted protease inhibitor (PI) to a dolutegravir (Tivicay)-based regimen maintained viral suppression just as well, according to a randomized trial out of Kenya.
Among a cohort... (Source: MedPage Today Infectious Disease)
Source: MedPage Today Infectious Disease - June 26, 2023 Category: Infectious Diseases Source Type: news
Second-Line Switch to Dolutegravir Noninferior in HIV
FRIDAY, June 23, 2023 -- For patients with HIV without genotype information, a second-line switch to dolutegravir is noninferior to a regimen containing a ritonavir-boosted protease inhibitor (PI), according to a study published in the June 22 issue... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - June 23, 2023 Category: Pharmaceuticals Source Type: news
